Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE)

Annals of the New York Academy of Sciences

Volumn 987, Issue , 2003, Pages 188-198

  Davidson, Anne ^a   Wang, Xiaobo ^a   Mihara, Masahiko ^a,b   Ramanujam, Meera ^a   Huang, Weiqing ^a   Schiffer, Lena ^a   Sinha, Jayashree ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

B cells; Co stimulatory blockade; SLE

Indexed keywords

ANTIBODY; ANTIGEN; CD40 LIGAND; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOUBLE STRANDED DNA; HYBRID PROTEIN; ICOS IMMUNOGLUBULIN; IMMUNOGLOBULIN G; PD 1 LIGAND IMMUNOGLOBULIN; REAGENT; TACI IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL ACTIVITY; CELL INTERACTION; CELLULAR IMMUNITY; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE MODEL; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALIA; MURINAE;

EID: 0038240916     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb06048.x     Document Type: Conference Paper

References (45)

1. MIHARA, M. et al. 2000. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J. Clin. Invest. 106: 91-101.
2. WANG, X. et al. 2002. Mechanism of action of combined short term CTLA4Ig and anti-CD40L in murine SLE. J. Immunol. 168: 2046-2053.
3. HAN, S. et al. 1995. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J. Immunol. 155: 556-567.
4. HOWLAND, K.C. et al. 2000. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J. Immunol. 164: 4465-4470.
5. FOY, T.M. et al. 1994. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J. Exp. Med. 180: 157-163.
6. THIENEL, U., J. LOIKE & M.J. YELLIN. 1999. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell. Immunol. 198: 87-95.
7. SCHWEITZER, A.N. & A.H. SHARPE. 1998. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J. Immunol. 161: 2762-2771.
8. REDDY, B. et al. 2001. The effect of CD28/B7 blockade on alloreactive T and B cells after liver cell transplantation. Transplantation 71: 801-811.
9. CARRENO, B.M. & M. COLLINS. 2002. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20: 29-53.
10. RILEY, J.L. et al. 2001. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. J. Immunol. 166: 4943-4948.
11. KIRK, A.D. et al. 1997. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA 94: 8789-8794.
12. GRIGGS, N.D. et al. 1996. The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells. J. Exp. Med. 183: 801-810.
13. LIPSKY, P.E. 2001. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2: 764-766.
14. FINCK, B.K., P.S. LINSLEY & D. WOFSY. 1994. Treatment of murine lupus with CTLA4Ig. Science 265: 1225-1227.
15. MOHAN, C. et al. 1995. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 154: 1470-1480.
16. DAIKH, D.I. et al. 1997. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J. Immunol. 159: 3104-3108.
17. DAIKH, D.I. & D. WOFSY. 2001. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166: 2913-2916.
18. SATER, R.A., P.C. SANDEL & J.G. MONROE. 1998. B cell receptor-induced apoptosis in primary transitional murine B cells: signaling requirements and modulation by T cell help. Int. Immunol. 10: 1673-1682.
19. REININGER, L. et al. 1996. Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZB x NZW)F1 mice. J. Exp. Med. 184: 853-861.
20. RATHMELL, J.C. et al. 1998. Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells. J. Exp. Med. 188: 651-659.
21. TARLINTON, D. 1998. Germinal centers: form and function. Curr. Opin. Immunol. 10: 245-251.
22. HANDE, S., E. NOTIDIS & T. MANSER. 1998. Bcl-2 obstructs negative selection of autoreactive, hypermutated antibody V regions during memory B cell development. Immunity 8: 189-198.
23. MAMULA, M.J. 1998. Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes. Immunol. Rev. 164: 231-239.
24. MANSER, T. et al. 1998. The roles of antibody variable region hypermutation and selection in the development of the memory B-cell compartment. Immunol. Rev. 162: 183-196.
25. SLIFKA, M.K. & R. AHMED. 1998. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr. Opin. Immunol. 10: 252-258.
26. ASH-LERNER, A. et al. 1997. Expression of an anti-DNA-associated VII gene in immunized and autoimmune mice. J. Immunol. 159: 1508-1519.
27. SINHA J. et al. 2001. Short term costimulatory blockade combined with cyclophosphamide does not abrogate glomerular deposition of antibodies but attenuates the kidney inflammatory response. [Abstract.] Arthritis Rheum. 44: S397.
28. CHAN, O.T., M.P. MADAIO & M.J. SHLOMCHIK. 1999. The central and multiple roles of B cells in lupus pathogenesis. Immunol. Rev. 169: 107-121.
29. MIYATA, M. et al. 2001. CpG-DNA derived from sera in systemic lupus erythematosus enhances ICAM-1 expression on endothelial cells. Ann. Rheum. Dis. 60: 685-689.
30. HUTLOFF, A. et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397: 263-266.
31. DONG, C. et al. 2001. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409: 97-101.
32. FREEMAN, G.J. et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192: 1027-1034.
33. NISHIMURA, H. & T. HONJO. 2001. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 22: 265-268.
34. YU, G. et al. 2000. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat. Immunol. 1: 252-256.
35. THOMPSON, J.S. et al. 2001. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293: 2108-2111.
36. BATTEN, M. et al. 2000. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 192: 1453-1466.
37. SCHNEIDER, P. et al. 1999. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189: 1747-1756.
38. ROLINK, A.G. & F. Melchers. 2002. BAFFled B cells survive and thrive: roles of BAFF in B-cell development. Curr. Opin. Immunol. 14: 266-275.
39. DO, R.K. et al. 2000. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J. Exp. Med. 192: 953-964.
40. ZHANG, J. et al. 2001. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166: 6-10.
41. MACKAY, F. et al. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190: 1697-1710.
42. DE SMEDT, T. et al. 2002. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J. Immunol. 168: 661-670.
43. JACQUOT, S. 2000. CD27/CD70 interactions regulate T dependent B cell differentiation. Immunol. Res. 21: 23-30.
44. WANG, J. et al. 2001. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J. Clin. Invest. 108: 1771-1780.
45. SUN, Y. et al. 2002. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J. Immunol. 168: 1457-1465.